Form 4: CEO Converts Note to Preferred Stock in Provectus

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock, which is convertible into common stock.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted an 8% unsecured convertible promissory note (the "2025 Note") into Series D-1 Convertible Preferred Stock.
• The conversion occurred on February 20, 2026, at a price of $2.862 per share of Series D-1 Convertible Preferred Stock.
• This transaction resulted in the acquisition of 47,180 shares of Series D-1 Preferred Stock.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless converted earlier.
• Following this transaction, Mr. Pershing beneficially owns 1,245,000 shares of Series D-1 Convertible Preferred Stock and 2,660,987 shares of Common Stock.
• The 2025 Note was originally issued as part of the Issuer's 2025 Financing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the CEO's conversion of debt to equity demonstrates continued commitment and aligns his interests with shareholders, though potential future dilution is a consideration.

Positives

• The conversion of the 2025 Note into equity reduces the company's debt obligations, strengthening the balance sheet.
• Increased equity ownership by the CEO aligns management's interests with those of shareholders.

Negatives

• The potential future conversion of preferred stock into common stock could lead to dilution for existing common shareholders.

Risks

• Potential future dilution of common stock if the Series D-1 Convertible Preferred Stock is converted into common shares.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider conversions of debt to equity, particularly by a CEO, can be viewed as a vote of confidence in the company's long-term prospects, common in the biotechnology sector where capital structure management is crucial for funding R&D and operations.

Related Party Transactions

• The conversion of an 8% unsecured convertible promissory note held by CEO Edward Pershing into Series D-1 Convertible Preferred Stock constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution of common stock upon conversion of Series D-1 Preferred Stock, but also a signal of management's long-term commitment.

Next Steps

• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on December 31, 2028, unless converted earlier.

Key Dates

Recommendation

The filing details a pre-scheduled conversion of a convertible note held by the CEO into preferred stock, which is a routine insider transaction. While it signals continued alignment of management's interests with shareholders, it does not present new information that would fundamentally alter the investment thesis for Provectus Biopharmaceuticals, warranting a 'hold' recommendation based solely on this filing.

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, Form 4, Insider Transaction, Convertible Note, Preferred Stock, Common Stock, Equity Conversion, CEO, Director, Biopharmaceuticals